Cansortium Reports First Quarter 2022 Financial Results
- Q1 Revenue up 30% YoY to a Record
- Q1 Adjusted EBITDA up 42% YoY to a Record
- Cansortium Reaffirms 2022 Guidance of
"As highlighted on our last quarterly report on
- Revenue increased 30% to
$19.7 million compared to$15.1 million . Florida revenue increased 26.6% to$16.6 million compared to$13.1 million .- Adjusted gross profit1 increased 19% to
$11.5 million or 58.6% of revenue, compared to$9.7 million or 64.2% of revenue. - Adjusted EBITDA increased 42% to
$6.2 million or 31.5% of revenue, compared to$4.4 million or 29.0% of revenue. - At
March 31, 2022 , the Company had approximately$7.7 million of cash and cash equivalents and$67.5 million of total debt, with approximately 252.3 million fully diluted shares outstanding (based on treasury stock method and share price onMay 27 , 2022).
__________________ |
1 Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations. |
- In
Florida , the Company anticipates opening 4-6 new stores in 2022. Four of these locations are already under contract and under construction. - On
April 20 ,Cansortium opened its thirdPennsylvania dispensary inAnnville . - The Company anticipates filing both its 2021 audited annual financial statements and first quarter 2022 unaudited interim financial statements by
June 8, 2022 .Cansortium expects to host a conference call for shareholders and prospective investors shortly thereafter.
The Company continues to expect revenue in 2022 to range between
Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.
Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
For further information: www.getfluent.com
Company Contact
(850) 972-8077
investors.getfluent.com
Investor Relations Contact
Elevate IR
(720) 330-2829
investors@cansortiuminc.com
|
|||
Statement of operations |
|||
For the three months ended |
|||
(USD '000) |
|||
Three months ended |
|||
|
|
Variance |
|
Revenue, net of discounts |
$ 19,712 |
$ 15,116 |
$ 4,596 |
Cost of goods sold |
8,166 |
5,407 |
2,759 |
Adjusted gross profit (1) |
11,546 |
9,709 |
1,837 |
Adjusted gross margin (1) |
58.6% |
64.2% |
-5.7% |
Realized fair value of increments on inventory sold |
(6,824) |
(4,593) |
(2,231) |
Unrealized change in fair value of biological assets |
1,198 |
6,879 |
(5,681) |
Gross profit |
5,920 |
11,995 |
(6,075) |
Gross margin |
30.0% |
79.4% |
-49.3% |
Expenses: |
|||
General and administrative |
2,841 |
3,289 |
(448) |
Share-based compensation |
100 |
3,232 |
(3,132) |
Sales and marketing |
4,087 |
3,546 |
541 |
Depreciation and amortization |
1,664 |
1,530 |
134 |
Total expenses |
8,692 |
11,597 |
(2,905) |
Income (Loss) from operations |
(2,772) |
398 |
(3,170) |
Discontinued operations |
2 |
(2) |
4 |
Other expense (income): |
|||
Finance costs, net |
3,657 |
3,130 |
527 |
Change in fair market value of derivative |
1,702 |
(408) |
2,110 |
Loss on disposal of assets |
- |
48 |
(48) |
Other expense |
(2) |
(113) |
111 |
Total other (income) expense |
5,357 |
2,657 |
2,700 |
Income (Loss) before taxes |
(8,131) |
(2,257) |
(5,874) |
Income taxes |
2,013 |
2,838 |
(825) |
Net income (loss) |
(10,144) |
(5,095) |
(5,049) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/cansortium-reports-first-quarter-2022-financial-results-301558237.html
SOURCE